![Mark Lundie](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mark Lundie
Directeur/Membre du Conseil chez Clinical Trials Ontario
Profil
Mark Lundie is currently serving as a Board of Director at Ontario Genomics Institute (Private Equity) and as a Director at Clinical Trials Ontario.
He previously worked as the Chairman at Centre For Probe Development & Commercialization.
Postes actifs de Mark Lundie
Sociétés | Poste | Début |
---|---|---|
Clinical Trials Ontario
![]() Clinical Trials Ontario Miscellaneous Commercial ServicesCommercial Services Clinical Trials Ontario operates as a research and development company for various diseases. The company was founded in 2012 and is headquartered in Toronto, Canada. | Directeur/Membre du Conseil | - |
Ontario Genomics Institute (Private Equity)
![]() Ontario Genomics Institute (Private Equity) Investment ManagersFinance Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London. | Directeur/Membre du Conseil | - |
Anciens postes connus de Mark Lundie
Sociétés | Poste | Fin |
---|---|---|
Centre For Probe Development & Commercialization
![]() Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | Président | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 3 |
---|---|
Clinical Trials Ontario
![]() Clinical Trials Ontario Miscellaneous Commercial ServicesCommercial Services Clinical Trials Ontario operates as a research and development company for various diseases. The company was founded in 2012 and is headquartered in Toronto, Canada. | Commercial Services |
Centre For Probe Development & Commercialization
![]() Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | Health Technology |
Ontario Genomics Institute (Private Equity)
![]() Ontario Genomics Institute (Private Equity) Investment ManagersFinance Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London. | Finance |